Key result
Emerging circulating biomarkers show potential for enhancing cardiovascular risk prediction.
Why the study?
Cardiovascular disease remains the primary cause of global mortality, and lipid levels alone do not fully capture atherosclerosis status, driving research into novel cardiovascular biomarkers.
This review highlights several emerging circulating biomarkers, such as GDF-15, galectin-3, and microRNAs, that may enhance cardiovascular risk prediction beyond traditional lipid profiles.
May refine risk stratification beyond lipids; leaves open prospective validation before clinical adoption.
Cardiovascular disease (CVD) continues to be the primary cause of mortality worldwide, underscoring the importance of identifying additional cardiovascular risk factors. The consensus is that lipid levels alone do not fully reflect the status of atherosclerosis, thus necessitating extensive research on cardiovascular biomarkers. This review encompasses a wide spectrum of methodologies for identifying novel risk factors or biomarkers for CVD. Inflammation, oxidative stress, plaque instability, cardiac remodeling, and fibrosis play pivotal roles in CVD pathogenesis. We introduce and discuss several promising biomarkers-namely, osteocalcin, angiogenin, lipoprotein-associated phospholipase A2, growth differentiation factor 15, galectin-3, growth stimulation expressed gene 2, and microRNAs, all of which have potential implications in the assessment and management of cardiovascular risk.
No takes yet. Share an insight, caveat, or question.
Da Young Lee (2024) conducted a review in Cardiovascular disease. Circulating biomarkers (Osteocalcin, Angiogenin, Lp-PLA2, GDF-15, Galectin-3, ST2, miRNAs) was evaluated. Emerging circulating biomarkers, including osteocalcin, angiogenin, Lp-PLA2, GDF-15, galectin-3, ST2, and microRNAs, show potential for enhancing cardiovascular risk prediction.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: